Citalopram is marketed as a racemate (50:50) mixture of the S(+)-enantiomer and R(-)-enantiomer and the active S(+)-enantiomer (escitalopram) that possess inhibitory effects. Citalopram was introduced in Sweden in
Introduction
Antidepressants are commonly found in individuals who commit suicide. In Sweden, antidepressants have been found in 12% of men and in 26% of women committing suicide. However, toxicity of an antidepressant was the probable cause of death in only 2.1% of the men and 7.9% of the women (1, 2) . Attempts to separate antidepressant effects from adverse drug reactions led to the development and introduction of selective serotonin reuptake inhibitors (SSRI), representing an important advance in the pharmacotherapy of psychiatric disorders (3, 4) .
Citalopram (Cit), a racemate (50:50) of the S(+)-enantiomer (S-Cit) and the R(-)-enantiomer (R-Cit), is an antidepressant drug within the SSRI group, with no, or minimal, effect on noradrenaline and dopamine reuptake within the SSRI group (5) . Cit was introduced in Sweden 1992 and is the most frequently used antidepressant to date in Sweden.
In vitro studies have shown that the inhibitory effect on serotonin reuptake resides in the single enantiomer S-Cit. In 2002, S-Cit (escitalopram, Cipralex ® ) was introduced onto the Swedish market for treatment of depression and anxiety disorders (6) (7) (8) .
For those given 40 mg racemate daily, steady-state peak serum concentrations were 0.074 ± 0.02 µg/mL for R-Cit and 0.05 ± 0.02 µg/mL for S-Cit (9), attained after 3.3 ± 1.4 h. However, the half-lives were 34.8 ± 4.3 h and 46.9 ± 10 h for S-Cit and R-Cit, respectively. When 30 mg of the pure enantiomer is given once daily, steady-state peak serum concentration was 0.06 ± 0.03 µg/mL, attained after 4.1 ± 2.7 h. The half-life was 32.5 ± 14.2 h (8) .
Both Cit and S-Cit are metabolized by the cytochrome P450 enzymes (10, 11) . In the first step CYP3A4, CYP2C19, and CYP2D6 catalyze the metabolism of the mother substance to the demethylated metabolite, whereas the further metabolism to the didesmethylated metabolite is catalyzed by CYP2D6 (12) (13) (14) (15) (16) (17) . There is also a stereoselective metabolism for the racemic drug. It has been shown that the R-and S-enantiomers are metabolized by the same isoenzymes, but at different rates (9) . The S-enantiomer of Cit was metabolized faster than the Renantiomer, but in further metabolism, the R-DCit is favored over S-DCit (13) . The CYP3A4 and CYP2C19 enzyme activity is inducible and can be inhibited by substrates (18, 19) . CYP2D6 is a non-inducible enzyme, although the ability for induction of drug-metabolizing enzymes has been of great importance for increasing their detoxification potential (20) .
The morbidity and mortality caused by tricyclic antidepres-
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sant overdose are well recognized, and the newer antidepressants and SSRIs are thought to be safer in overdose (21) (22) (23) (24) . Even though the SSRIs are considered less toxic compared with tricyclic/tetracyclic antidepressants, the risk of developing serious side effects such as ECG abnormalities and convulsions have been seen for Cit when larger doses have been ingested by patients (25, 26) . Furthermore, fatal overdoses have been reported where Cit alone was the cause of death (27) (28) (29) , although these are rare. In cases with lethal outcomes, other central nervous system (CNS)-active substances are usually found together with Cit.
Data on S-Cit regarding accidental and intentional exposure are limited (30, 31) . Data on the toxicity of each of the enantiomers in humans have not been published, nor have data on blood concentrations of the enantiomers involving intoxication. There are, however, no data for S-Cit in postmortem cases because the methods used for drug screening at the forensic laboratories are not enantioselective. Without an enantioselective method, it is not possible to separate and measure the concentrations of the S-and R-enantiomers as the concentrations found with the non-enantioselective method are from Cit (the sum of S-Cit and R-Cit) or S-Cit. In Sweden, the number of cases suspected to be positive for Cit using the screening procedure has been approximately 250-300 annually for the past 10 years (1995-2004) (2) . The lack of knowledge of how many of these cases, between 2002 and 2004, involved SCit made further scrutiny of a selection of the Cit-positive samples interesting.
The aims of the present study were to confirm whether the blood levels of citalopram found during routine screening with a non-enantioselective gas chromatography-nitrogenphosphorus detection (GC-NPD) method were from intoxication with Cit (the racemic drug) or S-Cit (the single enantiomer), using an enantioselective high-performance liquid chromatography (HPLC) method, as well as to study the genotype for the isoenzymes CYP2D6 and CYP2C19.
Materials and Methods

Case selection
We selected 50 samples from 270 Cit-positive cases found by screening from November 2003 to December 2004 for enantioselective HPLC and genotyping for CYP2D6 and CYP2C19. The samples were selected on the basis of all available data on concomitant drug history and drug bioanalytical outcomes and data from the forensic medicine record forms, including medical interpretation and cause of death as assigned by the forensic pathologist. All cases found with a history of only SCit (n = 7), and one with a history of S-Cit and Cit, were therefore selected. The remaining 42 samples were selected consecutively from the registration record at the Department of Forensic Genetics and Forensic Toxicology. This was because the "older" the case, the closer it was to its "final" medical interpretation and causality assignment by the forensic pathologist. Decomposed samples were excluded, and the next case was assessed as a candidate for inclusion. The same reasoning was also used if, for example, the sample stored was found too be of too little matrix (too few milliliters of blood) or otherwise suspected to be problematic for further drug analytical work-up.
Sample collection
Femoral blood, collected as routine procedure from autopsy cases, was used. Potassium fluoride was added as a preservative, and the samples were thereafter analyzed by drug screening and subsequently for enantioselective analysis and genotyping.
Non-enantioselective GC-NPD method
The concentrations of Cit and DCit and the concentrations of S-Cit and its demethylated metabolite (S-DCit) were determined using the same GC-NPD method also used for the other drugs, as previously described in detail (29) . The method had a linear calibration range between 0.05 and 5.00 µg/g, with a coefficient of variation at 0.01 µg/g of 14% and 24% for Cit and DCit, respectively. The samples were analyzed at the Department of Forensic Genetics and Forensic Toxicology, Linköping, Sweden.
Enantioselective HPLC method
Determination of the concentration of the S-and R-enantiomers of Cit, DCit, and DDCit was carried out by HPLC with fluorescence detection on an acetylated β-cyclodextrin column (Cyclobond I 2000 Ac 250 × 4.6-mm column, Astec, Whippany, NJ) (32) (33) (34) . The HPLC system consisted of a Gina 50 autosampler, Dionex 680 pump (Dionex, Sunnyvale, CA), and a Waters 474 fluorescence detector (Waters, Milford, MA), and the temperature of the column was held constant at 30°C by a column/heater/chiller 7955 (Jones Chromatography, Hengoed, U.K.).
Briefly, extraction of femoral whole blood was carried out using solid-phase extraction on Isolute C2 (100 mg) endcapped columns (International Sorbent Techonology, Hengoad, U.K.). The blood (0.1-0.5 g) was diluted with 3 mL of 5:95 acetonitrile/0.025 M phosphate buffer followed by vortex mixing, sonification, and centrifugation, before it was loaded onto the pre-conditioned solid-phase column. The column was washed with ultra-pure water and acetonitrile before elution of the substances with 1% acetic acid in methanol. After evaporation, the samples were redissolved in mobile phase and injected onto the acetylated β-cyclodextrin column where the S-and R-enantiomers of Cit, DCit, and DDCit were separated, followed by fluorescence detection (excitation wavelength 240 nm and emission wavelength 300 nm) (33, 35) . Calculations of standard curves were performed using the Chromeleon (Dionex) integration system. Limits of quantification for all analytes are 0.002 µg/g blood and the standard curves were linear over a concentration range of 0.01 to 1.6 µg/g with a correlation between the GC-NPD and HPLC method for total Cit (r = 0.9855, p < 0.001) and DCit (r = 0.9148, p = 0.001) (33) . The samples were analyzed at the department of Clinical Pharmacology, University Hospital, Linköping, Sweden.
Subgroups
According to an earlier study where we measured the levels of Cit enantiomers and metabolites in postmortem cases genotyped for CYP2D6 and CYP2C19, the Cit cases were divided into P/M groups (Parent compound/Major metabolite), reflecting a normal ratio at steady state (group 1); a somewhat elevated ratio but one regularly found in postmortem cases (group 2); and very high ratios indicating acute ingestion (group 3). The P/M-group criteria were as follows: group 1 P/M ratios up to 4, group 2 P/M ratios between 4 and 10, and group 3 P/M ratios above 10 (33). We found increasing S/R ratios with increasing concentrations of Cit and that high Cit S/R ratios were associated with high P/M ratio, and may be an indication of intake of the drug only a few hours or so before death (33) .
DNA extraction
Genomic DNA was extracted from the femoral blood according to the dodecyltrimethylammonium bromide/cetyltrimethylammonium bromide method (36) . Extracted DNA samples were stored at -20°C until analyzed. Genotyping was performed at the Department of Forensic Genetics and Forensic Toxicology.
Genotyping for CYP2D6 and CYP2C19
Polymerase chain reaction (PCR) and pyrosequencing was used for CYP2D6 genotyping for the following alleles: *1 (wt), *2 (2850C>T), *3 (2549A>del), *4 (1846G>A), and *6 (1707T>del) (37) . The gene copy number was also determined (38) . All alleles were identified by single nucleotide polymorphism analysis using pyrosequencing (37) . The starting material for pyrosequencing was a PCR amplified, 5'-biotinylated, single-strand DNA template with a sequencing primer hybridized to it. In order to obtain this starting material, PCR amplification was performed in a total volume of 25 µL with a 5'-biotinylated primer, using 10 ng of human genomic DNA and Ready-To-Go PCR Beads (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instructions. The CYP2D6*2 forward primer was GGCTACCC-CGTTCTGTCCC and the CYP2D6*2 sequencing primer was TTCAATGATGAGAACCTG.
Each of the biotinylated PCR products was immobilized onto streptavidin-coated Sepharose beads (Streptavidin Sepharose HP, Amersham Biosciences). Sepharose beads (3 µL) were mixed with binding buffer, Milli-Q water, and PCR products, to a final volume of 80 µL per well. The plate was mixed-incubated for 10 min at 25°C (1300 rpm). After immobilization, the beads were washed according to the manufacturer's instructions, using the vacuum prep tool (Biotage AB, Uppsala, Sweden), and finally released into 45 µL of annealing buffer containing 15 pmol of each sequencing primer. Primer annealing was performed and the samples were analyzed on a PSQ 96 PA MA system (Biotage) according to standard protocols.
The allele CYP2D6*5 (gene deletion) was identified using multiplex long PCR (39) , with some minor modifications. The PCR products were separated by gel electrophoresis in a 0.8% agarose gel and identified.
Multiplex PCR and pyrosequencing was used for CYP2C19 genotyping (40, 41) . The three alleles with corresponding polymorphism were CYPC19*2 (681G>A), *3 (636G>A), and *4 (1A>G). In order to obtain the biotinylated PCR product, a multiplex PCR amplification was performed in a total volume of 25 µL, using QIAGEN multiplex PCR kit (VWR International, Lidingö, Sweden) and 10 ng of human genomic DNA.
Pyrosequencing was performed for determination of the CYP2C19 alleles in the same way as described for CYP2D6.
CYP-genotype outcomes were categorized into extensive metabolizers (EM), carriers of two normally active alleles; intermediate metabolizers (IM), carriers of only one active allele; poor metabolizers (PM), carriers of two deficient alleles; and sometimes ultrarapid metabolizers (UM), carriers of multiple copies of functional alleles (10) .
Statistical methods
When comparing more than two groups, analysis of variance was used. A p-value < 0.05 was regarded as significant. Results are given as mean ± standard deviation (SD) or median and range. All statistical analyses were performed using Statistica™ 6.0 from StatSoft (Tulsa, OK).
Ethics
The Research Ethics Committee of Linköping University, Linköping, Sweden, approved the study.
Results
General information about the selected cases
Among the 50 selected cases, 22 were women (44%) and 28 were men (56%). Ages ranged between 19 and 89 years (median age 62.5 years, mean age 60.8 ± 18.6 years).
Age, sex, cause, and manner of death, together with the total concentrations of parent compound and main metabolite, S/R-ratios, outcome of other analytical findings in the screening, and genotype results are listed in Table I . The demographic data show that the distribution of age and gender was in agreement with the non-selected (220 cases), and all 270 cases.
There were 19 different specific, primary causes leading to death among the selected 50 cases. Intoxication was the cause of death in 16 cases (32%). Seventy-one different drugs were detected. In 15 cases (30%), Cit was the only drug identified by the toxicological analysis, and 3 cases (6%), S-Cit was the only drug identified. Other drugs found in addition to Cit or S-Cit were antidepressants (n = 6), ethanol (n = 12), paracetamol (n = 7), zoplicone (n = 5), and diazepam (n = 6). Alcohol was involved in 21 cases (42%) with Cit and 5 cases (10%) with S-Cit. The cause of death was given as intoxication by Cit and alcohol in 2 cases, and intoxication by S-Cit and alcohol in 1 case.
Enantioselective analysis
Representative chromatograms are presented in Figure 1 , from extracts of whole blood standard ( Figure 1A) ; a case in which racemic Cit had been ingested ( Figure 1B) ; a case in which only the pure enantiomer S-Cit and its metabolites were found ( Figure 1C) ; and in which a mixture of the racemic and the pure enantiomer had been ingested ( Figure 1D ). All the results from the enantioselective analysis are presented in Table II . The concentrations in femoral blood (mean ± SD) in all cases were 0.77 ± 1.60 (range 0.05-9.65) for Cit, 0.16 ± 0.16 (range 0.01-0.80) for DCit, and 0.033 ± 0.031 (range 0.003-0.146) for DDCit (µg/g). Analysis of the selected 50 cases with the enantioselective HPLC method resulted in 10 cases (20%) without any detectable levels of R-Cit.
The results after dividing the cases into subgroups: cases found only with Cit (n = 38) or the pure enantiomer (n = 10) are shown in Table III for Cit/DCit and S-Cit/S-DCit (case numbers 32 and 41 are withdrawn).
The selection process, enantioselective analysis, and outcome are summarized in Figure 2 .
The enantioselective analysis confirmed that 5 of the 7 cases with a history of access to S-Cit had only S-Cit (numbers 8, 22, 25, 33, and 48), but the other two cases (15 and 18) had significant amounts of R-Cit. The other 5 S-Cit cases (numbers 6, 7, 16, 28, and 40) were "new" and could not have been found with the non-enantioselective screening method. Furthermore, enantioselective analysis showed that both the racemate and the enantiomer had been ingested in two cases (32 and 41) , where the S/R ratios were 2.20 and 3.71 compared to 0.69 for Cit cases (n = 38). In the case number 41, access to the racemic and the enantiomer was found in the case history.
According to the P/M-group criteria, in P/M-group 1 was 31 cases (62%), 14 in P/M-group 2 (28%), and 5 in P/M-group 3 (10%). The results after dividing the cases into 3 P/M groups are shown in Table III . 
Genotyping
All 50 cases were genotyped for CYP2D6 and CYP2C19 (Table  I) . PMs were found for CYP2D6, 6% (n = 3) and for CYP2C19, 8% (n = 4). There were 4% (n = 2) UMs of CYP2D6 (one or more active alleles). IMs for CYP2D6 were 16 cases with one defect allele (*3, *4, *6, or *5) and 13 for CYP2C19 (*2, *3, or *4). The results after dividing the cases into PMs and EMs for the Cit cases are shown in Table III . In the 10 cases with only S-Cit, no PMs were found. The relative frequencies of the different genotypes and allele frequencies were calculated for CYP2D6 (Table IV) and for CYP2C19 (Table V) .
Discussion
Among the 50 cases analyzed with an enantioselective HPLC method, we have confirmed that in 20% of the cases (n = 10) only S-Cit was responsible for a positive screen for Cit. It was evident that in these 10 cases, no detectable level of R-Cit was found. Moreover, because the elimination half-life of the S-form of Cit is shorter than that of the R-form, it must therefore be correct to state that these 20% of the fatal cases had ingested only S-Cit. This focus on S-Cit may be of particular interest when the racemic and the single enantiomer are concurrent in the market, although the prescription rate of this drug compared to the racemic leading antidepressant drug Cit in Sweden was quite low during the period of data collection.
However, an interesting observation for the 7 cases, with a history of access to S-Cit was that only 5 proved to lack R-Cit in their blood, whereas 2 had significant amounts also of the Rform of citalopram. In those 2 cases, numbers 15 and 18, the P/M-and S/R-ratios were found to indicate that the individuals had been taking the racemic preparation, although not necessarily immediately before death. Thus, it cannot be excluded that these two cases had an "unknown" prescription, or at least access also to the racemic drug that probably in such a case was ingested some time before death, because the concentrations were low. Among the remaining 42 cases, 1 case with both Cit and S-Cit and 5 cases with S-Cit only were found by the enantioselective analysis, meaning that 14% of the cases, without a case history, had ingested S-Cit only or in combination with Cit. These cases signify the importance of having access to and routinely using an enantioselective method for phase-IV-surveillance of human toxicity for a drug like citalopram that occurs in both a racemic and an enantiomer-selective preparation form available for general prescription (i.e., in the naturalistic setting). Among the cases, 62% were categorized as P/M group 1 (ratio lower than 4), possibly indicating that for these selected cases, Cit or S-Cit was not ingested close to the time of death. This finding is verified by that the average S/R-ratio in P/M group 1 was 0.58 for the Cit cases and also in agreement with data from therapeutic clinical studies (42) . However, the relevance of the generally lower than 4 median P/M-ratio is difficult to assess correctly (at least on a group level), because some of the selected cases had taken only S-Cit or perhaps a mixture of racemic Cit and S-Cit. Using the P/M method, 10% of cases were judged as having ingested Cit in close relation to the time of death. Only two of these 50 cases (4%) were found to have very high (toxic) levels of Cit (9.65 and 6.69 µg/g) in femoral vein blood. The S/R-enantiomer ratio was 0.93 and 0.99 respectively, indicating a recent intake of the drug and that Cit rather than S-Cit was the drug involved in these cases.
The Cit-group (n = 38) in this study showed lower P/M values (4.6 SD ± 4.0) compared to the study by Holmgren et al. (33) , P/M ratio 9.14 ± 13.62, which also supports that in the present study more cases from P/M group 1 were included. Because only the sum of the two enantiomers is measured in the routine screening, it may be more relevant to find the "hidden" S-Cit cases in P/M-group 1. The P/M ratio of 3.7 for the S-Cit in postmortem is, however, higher than what has been found in patients, between 1.52 (women) and 2 (men) (43) .
In Sweden, a strictly standardized procedure is used for sampling of femoral blood to avoid contribution of possible "central" blood (44, 45) . Two experimental studies on postmortem redistribution of the enantiomers of Cit in rats show that the S/R and P/M ratios were unchanged before and after death (46, 47) , and moreover, any chiral inversion between the enantiomer has not been found (9) . Finally, in the setting of "routine" forensic pharmacology in Sweden today, a level of approximately 0.7 µg/g or above of Cit found in femoral vein blood at a postmortem bioanalysis can be considered to be a "toxic" level (i.e., if no other clinical data or considerations from the drug bioanalytical requesting pathologist accompany the patient or case) (29) . A total of 14 (28%), in this study, of the selected cases with postmortem Cit drug levels were found to be above the "potentially" toxic level of 0.7 µg/g in femoral vein blood. In this group of the "potentially" toxic level, no pure (43) . In our samples found with S-Cit, the mean concentration was 0.21 and none of the SCit cases were in P/M group 3. This indicates that no toxic levels were found in these S-Cit cases. In order to evaluate the genotyping result from this study, the genotyping outcome was compared with two earlier studies on genotyping of CYP2D6 and CYP2C19 in postmortem material. In the study by Holmgren et al. (33) , 52 cases were genotyped, and in the study by Zackrisson et al. (41) , 242 postmortem cases were compared with a reference group of 281 blood donors. In both studies, the prevalence of CYP2D6 PMs genotypes in postmortem was lower than in the general Caucasian population (10), 4.7% and 3.8%, respectively. Our study groups show a somewhat higher percentage of PMs (6.0%), but the frequency is still lower than in the general Caucasian population. The cause of death in this study for the PM group was intoxication in addition with Cit: ethanol and carbon monoxide (number 15), zopiclone and carbon monoxide (number 24), and ethanol, propiomazin, and zopiclone (number 47). As expected, in the Cit group the PM cases had approximately a twofold higher concentration than the non-poor metabolizers.
The relative allele frequency of CYP2D6 genotypes inclusive the lower frequency of CYP2D6*4 in this study are comparable with the fatal intoxication cases from Zackrisson et al. (41) , but the relative allele frequency for CYP2D6*5 (gene deletion) of 0.030 is lower in our study. There were 4% of UMs of CYP2D6 among these cases, which is in accordance with those expected in a Caucasian population (10) . In the comparing studies, UM was not investigated.
A higher percentage, 8%, of PMs of CYP2C19 was found in comparison with the study by Zackrisson et al. (41) , 2.1%, and none in the study by Holmgren et al. (33) , compared to 3% in the general population (10) . In the study by Holmgren et al. (33) , the genotyping for CYP2C19 was carried out with another method and not with the pyrosequencing assay that has been used in the two other studies. It is difficult to explain the different outcomes of genotyping in these three studies, but an explanation may be biased in the selection process. In one case (number 41), the cause of death was intoxication with more than one drug in addition to Cit/S-Cit.
If the prescription rate of S-Cit increases, we strongly recommend a prospective collection of only S-Cit cases in the future, in order to increase knowledge of a similar type of human toxicology surveillance as in the present report. We suggest that the procedure of scrutinizing toxicology data may be used more readily in the future. An increased knowledge, particularly of suspected toxicology in everyday clinical practices where CNS-active drugs are prescribed, would enhance drug safety.
Conclusions
Following the scrutiny of 50 selected cases during one year of those screening positive for Cit, it can be concluded that 1. With the introduction of the S-Cit, the single enantiomer, as many as 20% can be misinterpreted without access to an enantioselective method.
2. An unexpectedly high percent (8%) of PMs of CYP2C19 compared to the normal distribution of 3% were found, although a firmer conclusion to the relevance of these CYPisoenzyme expressions and fatality cannot be made at present.
3. With the introduction of other chiral switches, the access to an enantioselective method is necessary both in forensic toxicology as well as for therapeutic drug monitoring.
